Catalog makes Hartwig Medical Database easily searchable

Hartwig Medical Foundation maintains a catalog of the Hartwig Medical Database with whole-genome data on full tumor genomes: https://catalog.hartwigmedicalfoundation.nl. The database currently contains data on over 5,800 patients, including treatment and response data. In addition, this database contains RNA sequencing data from more than half of the patients.
Hartwig Medical Foundation’s mission is to provide the best possible care for today’s patient as well as the patient of tomorrow. An important part of this is making genomic and relevant clinical data available to research groups, with consent from the patients involved. The public catalog of Hartwig Medical Database makes it easy to gain insight into the available data, enabeling a quick and easy overview if there are tumor genomes in the database of interest to the researcher.

The catalog is interactive and the database can be viewed through flexible visualizations of different data types in multiple dimensions. Filtering is possible per data type, e.g. tumor type, biopsy location, age, gender, treatment given, treatment outcome and RNA availability.
This is the world’s largest publicly available dataset of its kind. It is available free of charge for research to improve the care for cancer patients of today and tomorrow. Hartwig Medical Foundation is grateful for the cooperation of so many patients, they have chosen to share their data for the benefit of science and other patients.
For the conditions and procedures for requesting access to the data, please visit our website.
Hartwig Medical Foundation collects data in collaboration with the CPCT, the Netherlands Cancer Institute and more than 40 Dutch hospitals with the consent of patients in various studies.
This unique source is continuously growing with increasing adaptation of complete genome diagnostics in regular healthcare in the Netherlands. Cancer of unknown primary origin is the first indication with a reimbursement title for this test and shows clearly the added value for patients in daily practice.
All news
Also read
Breast cancer awareness month
October is the international breast cancer awareness month. Breast cancer is the second most common type of cancer, and the …
Predicting therapy success based on gene expression
In addition to Whole Genome Sequencing of DNA, Hartwig Medical Foundation performs Whole Transcriptome Sequencing of RNA. Researcher Marjolein Lansbergen …
Clinical Cancer Genomics 2025: a cheerful boost for this rapidly emerging field
The atmosphere is buzzing, the excitement is almost tangible. This first Clinical Cancer Genomics Congress feels like an event that …
More and more cancer drugs are only suitable for a small group of patients. However, we are often not capable to find these patients. That is why every patient with metastatic cancer should be genetically screened before starting treatment.